Keyword: HPAPIs

News

Olon to Open New High Potency API Suite in US

29.01.2024 -

Olon Group is building a state-of-the-art High Potency Active Pharmaceutical Ingredient (HPAPI) suite at its Olon USA site in Concord, Ohio. This expands the company's...

News

Axplora’s Farmabios Gets cGMP Approval for New Production Unit in Italy

10.10.2023 -

Farmabios, a company of the Axplora group founded in 2022, has received the cGMP approval from AIFA (national public body regulating medicines for human use in Italy) for...

Strategy & Management

Containment Solutions for HPAPI Manufacturing

21.03.2023 -

Clear incentive for drug manufacturers to equip their production facilities with the capacity to process highly potent active pharmaceutical ingredients (HPAPIs). HPAPIs...

News

Lonza Completes HPAPI Expansion at Visp

29.09.2022 -

Lonza has completed of the expansion of its Highly Potent API (HPAPI) multipurpose suite at the Basel-based CDMO’s alpine production site in Visp, Switzerland, adding...

News

Merck Germany Doubles HPAPI Potential

24.06.2022 -

The Life Science business segment of German pharmaceuticals, chemicals and life sciences group Merck has widened its US plant for high-potent active pharmaceutical...

Chemistry & Life Sciences

Integrated Drug Development Models

13.05.2022 -

Interview with Giovanna Libralon, Senior Director Commercial Development Small Molecules at Lonza.

Strategy & Management

Expansions in High-Potency API Manufacturing

14.09.2020 -

DCAT Value Chain Insights rounds up recent expansion activity for highly potent drug substances and drug products.

Chemistry & Life Sciences

Understanding the Requirements of Safe HPAPI Manufacturing

11.09.2020 -

The pharmaceutical industry is increasingly focused on the development of specialized drug products with new treatment modalities, including previously undruggable...